Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Anima Biotech Inc.

Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases.

With novel biology that monitors the translation of proteins and proprietary cloud-based software, we identify drug candidates that modulate a target protein’s production.

We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets.

Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.

  • Date:Monday, February 11
  • Time:11:00 AM - 11:15 AM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23269
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Partnering
  • Company Website:www.animabiotech.com
  • Company HQ City:Bernardsville
  • Company HQ State:New Jersey
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:32 million
  • Year Founded:2014
  • Main Therapeutic Focus:Platform for Therapeutics
  • Lead Product in Development:Collagen I translation inhibitors
  • Development Phase of Primary Product:Discovery
  • Additional Information/Comments:July 23rd, 2018 Anima Biotech announced an agreement with Lilly for the discovery and development of translation inhibitors for several target proteins by using Anima’s Translation Control Therapeutics platform. The multi-year agreement is structured as an exclusive collaboration around several undisclosed Lilly targets. Anima will use its technology platform to discover lead candidates that are translation inhibitors of the Lilly targets. Lilly will be responsible for clinical development and commercialization of products resulting from the collaboration. Under the terms of the agreement, Anima will receive $30 million in upfront payments and $14 million in research funding. Anima is eligible to receive up to $1.05 billion if all future development and commercial milestones are achieved. Anima will additionally be entitled to low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
Speakers
Yochi Slonim
Anima Biotech Inc.
Back